These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 2953049)

  • 1. [Laboratory and clinical study with a new progestagen combined with ethinyl estradiol used in contraception].
    Galán G; Gayán P; Tisné L
    Rev Chil Obstet Ginecol; 1985; 50(4):317-24. PubMed ID: 2953049
    [No Abstract]   [Full Text] [Related]  

  • 2. The effects of desogestrel and ethinylestradiol combination in normal and hyperandrogenic young girls: speculations on contraception in adolescence.
    Venturoli S; Porcu E; Gammi L; Fabbri R; Paradisi R; Flamigni C; Patrono D; Capelli M; Paoletti C
    Acta Eur Fertil; 1988; 19(3):129-34. PubMed ID: 2976224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical evaluation of desogestrel, the first new-generation progestagen, practil 21, on 13,290 women and 74,967 cycles].
    Bilotta P; Favilli S
    Minerva Ginecol; 1987 Dec; 39(12):855-69. PubMed ID: 3329705
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effect and control of oral contraceptive Minesse (15 mkg EE/60 mkg Gestoden) on menstrual cycle and body weight].
    Krŭsteva
    Akush Ginekol (Sofiia); 2003; 42(5):46-8. PubMed ID: 14682015
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical study of a low-dose contraceptive--Femodene].
    Rachev E; Damianov L; Dukovski A; Katsarova M
    Akush Ginekol (Sofiia); 1995; 34(3):71-3. PubMed ID: 8787249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical studies with a new, low-dose oral contraceptive combination, containing 0.150 mg desogestrel and 0.020 mg ethinylestradiol.
    Acta Obstet Gynecol Scand Suppl; 1987; 144():1-44. PubMed ID: 2964165
    [No Abstract]   [Full Text] [Related]  

  • 7. Advantage of desogestrel containing pill in oral contraception: influence on blood lipids and LCAT activity.
    Pansini F; Ferrari C; Guerra S; Bassi P; Guzzinati N; Cocilovo G; Mollica G
    Clin Exp Obstet Gynecol; 1987; 14(3-4):136-9. PubMed ID: 2970349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
    Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C
    Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles.
    Gaspard U; Endrikat J; Desager JP; Buicu C; Gerlinger C; Heithecker R
    Contraception; 2004 Apr; 69(4):271-8. PubMed ID: 15033400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acne treatment with a new estroprogestinic biphasic combination containing desogestrel.
    Falsetti L
    Acta Eur Fertil; 1991; 22(5):283-6. PubMed ID: 1845752
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of lipid profile in adolescents during long-term use of combined oral hormonal contraceptives.
    Guazzelli CA; Lindsey PC; de Araújo FF; Barbieri M; Petta CA; Aldrighi JM
    Contraception; 2005 Feb; 71(2):118-21. PubMed ID: 15707561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol. Effects on the lipid profile.
    Creasy GW; Fisher AC; Hall N; Shangold GA
    J Reprod Med; 2003 Mar; 48(3):179-86. PubMed ID: 12698776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters.
    Winkler UH; Sudik R
    Contraception; 2009 Jan; 79(1):15-23. PubMed ID: 19041436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and metabolic aspects of the continuous use of a contraceptive association of ethinyl estradiol (30 microg) and gestodene (75 microg).
    Machado RB; Fabrini P; Cruz AM; Maia E; da Cunha Bastos A
    Contraception; 2004 Nov; 70(5):365-70. PubMed ID: 15504374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic profile of a continuous versus a cyclic low-dose combined oral contraceptive after one year of use.
    Rad M; Kluft C; de Kam ML; Meijer P; Cohen AF; Grubb GS; Constantine GD; Burggraaf J
    Eur J Contracept Reprod Health Care; 2011 Apr; 16(2):85-94. PubMed ID: 21417560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Divergent effects of two low-dose oral contraceptives on sex hormone-binding globulin and free testosterone.
    Jung-Hoffmann C; Kuhl H
    Am J Obstet Gynecol; 1987 Jan; 156(1):199-203. PubMed ID: 2948387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progestagen-dependent effect on some plasma proteins during oral contraception.
    Liukko P; Erkkola R; Bergink EW
    Gynecol Obstet Invest; 1988; 25(2):118-22. PubMed ID: 2967233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical study of the low dose oral contraceptive novynette].
    Uchikova E; Milchev N
    Akush Ginekol (Sofiia); 2003; 42(4):15-6. PubMed ID: 14577362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of oral contraceptives on acne. Apropos of a comparative study of Varnoline vs Diane in 69 women with acne].
    Levrier M; Degrelle H; Bestaux Y; Bourry-Moreno M; Brun JP; Sailly F
    Rev Fr Gynecol Obstet; 1988; 83(7-9):573-6. PubMed ID: 2973646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.